QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution 期刊论文 ANNALS OF TRANSLATIONAL MEDICINE, 2019, 卷号: 7, 期号: 12 作者:  Luo, Fan;  Zhang, Zhonghan;  Liao, Kunlun;  Zhang, Yang;  Ma, Yuxiang 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 Non-small cell lung cancer (NSCLC)  Response Evaluation Criteria in Solid Tumors (RECIST)  tumor shrinkage  X-tile  optimal threshold   Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy 期刊论文 RESEARCH IN MICROBIOLOGY, 2019, 卷号: 170, 期号: 2, 页码: 74-79 作者:  Li, Ruijuan;  Helbig, Linda;  Fu, Jun;  Bian, Xiaoying;  Herrmann, Jennifer 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/11 Escherichia coli Nissle 1917 (EcN)  Tumor-targeting therapy  Biosynthetic gene cluster  Cytotoxic compounds  Solid tumors   Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors 期刊论文 2019, 卷号: 12, 期号: 1, 页码: 9 作者:  Sun, Yongkun;  Yang, Lin;  Hao, Xuezhi;  Liu, Yutao;  Zhang, Jinwen 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/03 Advanced solid tumors  Chiauranib  Dose-escalation  Pharmacokinetics  Phase I study  Safety